Results 151 to 160 of about 949,412 (302)

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Brain health care accelerator: A primary care-centered model for scaling dementia diagnosis and care. [PDF]

Alzheimers Dement
Burns JM, Morris JK, Vidoni ED, Townley RA, Gillen LR, Smith TR, Jones JE, Nelson MB, Mudaranthakam DP, Perales-Puchalt J, Lewandowski T, Niedens CM, Parks AC, Brunette AM, Aschenbrenner AJ, Bucy TI, Forcino RC, Woodward JL.   +17 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Training for pediatric cannot intubate cannot oxygenate: surgical airway should replace needle cricothyrotomy. [PDF]

Front Disaster Emerg Med
Lehman AMB, Amstutz P, Moore JE, Johnson M, Obersteadt C, Williams D, Waxman MJ, Blubaugh M, Parikh A, Walsh TR, Bruegger DE, Sood SB, Malik AN, Pirotte A.   +13 more
europepmc   +1 more source

Master plan: banks can learn from Greensburg's recovery [PDF]

As bankers rebuild after the May 2007 tornado that obliterated this Kansas town, the need for financial institutions' emergency preparedness is reinforced.
Eric Robbins, Ken Spong
core  

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

The Impact of the Kansas Wheat Breeding Program on Wheat Yields, 1911–2006 [PDF]

This paper quantifies advances of the Kansas Agricultural Experiment Station (KAES) wheat breeding program for two time periods: (1) 1911 to 2006 and (2) 1977 to 2006.
Barkley, Andrew P., Chumley, Forrest G., Nalley, Lawton Lanier   +2 more
core   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

A Working Bibliography of the Languages of (Roughly) the Western United States ([-Athapaskan], [+Haida, Tsimshian, Wakashan])

Kansas Working Papers in Linguistics, 1983
University of Kansas Department of Linguistics editors
doaj   +1 more source

Correction: Optimal fluid management strategies in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Cardiovasc Med
Adamu UG, Muponda B, Tsabedze N.
europepmc   +1 more source